Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission

Next Previous
Trial Profile

A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cancer vaccine MUC-1 (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors Immutep Limited; Prima BioMed

Most Recent Events

  • 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
  • 26 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
  • 21 May 2015 Results of overall survival analysis in second remission patients published in a Prima BioMed media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top